September 15, 2012
Leaders in Pain Drug Development to Meet at 6th Annual Pain Therapeutics Summit
The world’s leading experts in the field of pain management and therapeutics will be meeting in San Francisco, California October 3rd and 4th for the 6th Annual Pain Therapeutics Summit.
This conference will provide attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products.
Nancy Lane, MD, Professor of Medicine & Rheumatology at UC Davis Health System will discuss the results from recent Phase 2 and 3 NFG inhibitor drug candidate studies. She will also address the status of their development and what the FDA Arthritis Advisory Committee’s recent recommendation to lift the hold on NGF inhibitors in clinical development means for the future of this class of pain therapeutics.
Sean Mackey, MD, Ph.D., Associate Professor of Anesthesiology at Stanford University will present research relating to recent advances in neuroimaging as an objective tool for the detection of pain. He will discuss recent data for both detection of acute and chronic pain, and potential applications in his presentation, Neuroimaging Based Pain Detection: Findings and Applications.
Dr. Peter French, CEO of Benitec Biopharma, will discuss a new strategy in pain control using gene therapy. This approach is a relatively low-risk option, and offers the prospect of a single treatment providing long term pain relief by using intrathecal delivery of lentiviral particles expressing shRNA constructs designed to inactivate the Protein Kinase C gamma gene in neurons of the spinal cord.
Dr. Daniela Salvemini of Saint Louis University will report the findings from her research that provides pharmacological rationale for therapeutic development of A3 Adenosine Receptor antagonists as novel analgesics for the management of chronic pain. She will describe their necessity, and how the effects of using this form of treatment are superior to using current analgesics.
Leaders from the pharmaceutical, biotech, device and medical communities attend this conference to learn about the latest advances in the treatment of various types of pain and to network with colleagues from industry, the non-profit sector, academia, the medical community, government and investors.
Please visit www.paintherapeuticsummit.com for a preliminary agenda and information on how to register to attend.